Profile
| Metric | Value |
|---|---|
| Full Name | HUTCHMED (China) Limited |
| Ticker | NASDAQ: HCM |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Specialty & Generic Drug Manufacturers |
| Country | Hong Kong |
| IPO | |
| Indexes | Not included |
| Website | hutch-med.com |
| Employees | 1,811 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $13.80 | |
| Price, 1D Change | +3.22% | |
| Market Cap | $2B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.88 | |
| Revenue | $631M | |
| Revenue, 1Y Change | -24.76% | |
| EPS | $0.22 | |
| EPS, 1Y Change | -62.69% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 10:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $0.22 | |
| EPS Estimate | $1.45 | |
| EPS Est. Change | +571.29% | |
| Revenue | $630.52M | |
| Revenue Estimate | $600.80M | |
| Revenue Est. Change | -4.71% | |
| Current Price | $13.80 | |
| Price Target | - | $21.26 |
| Price Tgt. Change | - | +54.06% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$0.06 | $0.22 | +474.22% | |
| $1.45 | N/A | +571.29% | |
| $0.46 | N/A | +112.81% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $668.78M | $630.52M | -5.72% | |
| $600.80M | N/A | -4.71% | |
| $707.82M | N/A | +12.26% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | -12.71% | |
| Price, 3Y | -17.76% | |
| Market Cap, 1Y | -12.26% | |
| Market Cap, 3Y | -16.38% | |
| Revenue, 1Y | -24.76% | |
| Revenue, 3Y | +77.05% | |
| EPS, 1Y | -62.69% | |
| EPS, 3Y | +117.62% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $13.80 | |
| SMA 200 | $15.21 | |
| SMA 200 vs Price | +10.22% | |
| SMA 50 | $14.25 | |
| SMA 50 vs Price | +3.25% | |
| Beta | 0.88 | |
| ATR | $0.35 | |
| 14-Day RSI | 42.71 | |
| 10-Day Volatility | 32.95% | |
| 1-Year Volatility | 52.69% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $630.52M | |
| EPS | $0.22 | |
| Gross Profit | $281.32M | |
| Gross Margin | 44.64% | |
| Operating Profit | -$44.96M | |
| Operating Margin | -62.50% | |
| Net Income | $38.19M | |
| Net Margin | 6.06% | |
| EBITDA | -$32.62M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.12 | |
| Current Ratio | 2.83 | |
| Quick Ratio | 2.70 | |
| Interest Coverage | - | |
| F-Score | - | |
| Altman Z-Score | 2.95 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | - | |
| PB Ratio | 1.93 | |
| EV/EBITDA | - | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $759.93M | |
| Cash & Equivalents | $836.11M | |
| Total Assets | $1.27B | |
| Current Assets | $1.07B | |
| Total Liabilities | $502.34M | |
| Current Liabilities | $376.56M | |
| Total Debt | $89.82M | |
| Short Term Debt | $26.30M | |
| Accounts Payable | $42.52M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $592.47M | |
| Operating Expenses | $326.28M | |
| Cost Of Goods Sold | $348.88M | |
| SG&A | $0.00 | |
| D&A | $12.34M | |
| Interest Expense | $0.00 | |
| Income Tax | $7.19M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $497.00K | |
| CFI | -$96.06M | |
| CFF | -$30.67M | |
| Capex | $17.93M | |
| Free Cash Flow | -$17.44M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Morgan Stanley | → | |
| B of A Securities | → | |
| Goldman Sachs | → | |
| Deutsche Bank | → | |
| Goldman Sachs | → | |
| Cantor Fitzgerald | → | |
| Cantor Fitzgerald | → | |
| Goldman Sachs | ||
| Goldman Sachs | ||
| Goldman Sachs | → |
Analyst sentiment
Institutional ownership
Screeners with HCM
Data Sources & References
- HCM Official Website www.hutch-med.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1648257/000141057825000377/0001410578-25-000377-index.htm
- HCM Profile on Yahoo Finance finance.yahoo.com/quote/HCM
- HCM Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/hcm
FAQ
What is the ticker symbol for HUTCHMED (China) Limited?
The ticker symbol for HUTCHMED (China) Limited is NASDAQ:HCM
Does HUTCHMED (China) Limited pay dividends?
No, HUTCHMED (China) Limited does not pay dividends
What sector is HUTCHMED (China) Limited in?
HUTCHMED (China) Limited is in the Healthcare sector
What industry is HUTCHMED (China) Limited in?
HUTCHMED (China) Limited is in the Specialty & Generic Drug Manufacturers industry
What country is HUTCHMED (China) Limited based in?
HUTCHMED (China) Limited is headquartered in Hong Kong
When did HUTCHMED (China) Limited go public?
HUTCHMED (China) Limited initial public offering (IPO) was on March 16, 2016
Is HUTCHMED (China) Limited in the S&P 500?
No, HUTCHMED (China) Limited is not included in the S&P 500 index
Is HUTCHMED (China) Limited in the NASDAQ 100?
No, HUTCHMED (China) Limited is not included in the NASDAQ 100 index
Is HUTCHMED (China) Limited in the Dow Jones?
No, HUTCHMED (China) Limited is not included in the Dow Jones index
When was HUTCHMED (China) Limited last earnings report?
HUTCHMED (China) Limited's most recent earnings report was on August 7, 2025
When does HUTCHMED (China) Limited report earnings?
The next expected earnings date for HUTCHMED (China) Limited is March 23, 2026